NCT04067336 2025-11-10First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid LeukemiaKura Oncology, Inc.Phase 1/2 Recruiting263 enrolled 1 FDA
NCT03069352 2025-09-30A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive ChemotherapyAbbViePhase 3 Completed211 enrolled 30 charts 2 FDA
NCT05918913 2025-09-05Expanded Access Program for RevumenibSyndax PharmaceuticalsNo longer available1 FDA